nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A7—Irinotecan—colon cancer	0.104	0.13	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.104	0.13	CbGbCtD
Triazolam—CYP3A7—Vincristine—colon cancer	0.0907	0.114	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.0907	0.114	CbGbCtD
Triazolam—CYP2C9—Capecitabine—colon cancer	0.0845	0.106	CbGbCtD
Triazolam—CYP3A5—Irinotecan—colon cancer	0.0778	0.0975	CbGbCtD
Triazolam—CYP2C8—Fluorouracil—colon cancer	0.0718	0.09	CbGbCtD
Triazolam—CYP3A5—Vincristine—colon cancer	0.068	0.0852	CbGbCtD
Triazolam—CYP2C9—Fluorouracil—colon cancer	0.0501	0.0628	CbGbCtD
Triazolam—CYP3A4—Irinotecan—colon cancer	0.0303	0.038	CbGbCtD
Triazolam—CYP3A4—Vincristine—colon cancer	0.0265	0.0332	CbGbCtD
Triazolam—Dysaesthesia—Fluorouracil—colon cancer	0.00578	0.0286	CcSEcCtD
Triazolam—Slurred speech—Fluorouracil—colon cancer	0.00559	0.0277	CcSEcCtD
Triazolam—Dysaesthesia—Capecitabine—colon cancer	0.00404	0.02	CcSEcCtD
Triazolam—Eye irritation—Fluorouracil—colon cancer	0.00293	0.0145	CcSEcCtD
Triazolam—Dysarthria—Irinotecan—colon cancer	0.00276	0.0137	CcSEcCtD
Triazolam—Dysarthria—Fluorouracil—colon cancer	0.00264	0.0131	CcSEcCtD
Triazolam—Memory impairment—Capecitabine—colon cancer	0.00223	0.011	CcSEcCtD
Triazolam—Deafness—Vincristine—colon cancer	0.00217	0.0108	CcSEcCtD
Triazolam—Hepatic failure—Vincristine—colon cancer	0.00216	0.0107	CcSEcCtD
Triazolam—Euphoric mood—Fluorouracil—colon cancer	0.00215	0.0106	CcSEcCtD
Triazolam—Eye irritation—Capecitabine—colon cancer	0.00205	0.0101	CcSEcCtD
Triazolam—Disorientation—Fluorouracil—colon cancer	0.00203	0.01	CcSEcCtD
Triazolam—Visual disturbance—Irinotecan—colon cancer	0.002	0.00989	CcSEcCtD
Triazolam—Amnesia—Fluorouracil—colon cancer	0.00193	0.00955	CcSEcCtD
Triazolam—Osteoarthritis—Irinotecan—colon cancer	0.00189	0.00937	CcSEcCtD
Triazolam—Urinary retention—Vincristine—colon cancer	0.00185	0.00915	CcSEcCtD
Triazolam—Dysarthria—Capecitabine—colon cancer	0.00185	0.00914	CcSEcCtD
Triazolam—Hearing impaired—Capecitabine—colon cancer	0.00184	0.00908	CcSEcCtD
Triazolam—Ataxia—Vincristine—colon cancer	0.00183	0.00905	CcSEcCtD
Triazolam—Osteoarthritis—Fluorouracil—colon cancer	0.00181	0.00898	CcSEcCtD
Triazolam—Coordination abnormal—Capecitabine—colon cancer	0.00178	0.0088	CcSEcCtD
Triazolam—Irritability—Fluorouracil—colon cancer	0.00173	0.00857	CcSEcCtD
Triazolam—Muscular weakness—Vincristine—colon cancer	0.00172	0.00849	CcSEcCtD
Triazolam—Ataxia—Fluorouracil—colon cancer	0.00171	0.00844	CcSEcCtD
Triazolam—Cramp muscle—Irinotecan—colon cancer	0.00171	0.00844	CcSEcCtD
Triazolam—Depressed level of consciousness—Capecitabine—colon cancer	0.00169	0.00834	CcSEcCtD
Triazolam—Muscular weakness—Fluorouracil—colon cancer	0.0016	0.00792	CcSEcCtD
Triazolam—Sweating increased—Irinotecan—colon cancer	0.0016	0.00789	CcSEcCtD
Triazolam—Dysuria—Vincristine—colon cancer	0.00157	0.00778	CcSEcCtD
Triazolam—Mental disability—Capecitabine—colon cancer	0.00152	0.0075	CcSEcCtD
Triazolam—Sleep disorder—Capecitabine—colon cancer	0.00146	0.00725	CcSEcCtD
Triazolam—Stomatitis—Vincristine—colon cancer	0.00146	0.00723	CcSEcCtD
Triazolam—Stomatitis—Irinotecan—colon cancer	0.00142	0.00704	CcSEcCtD
Triazolam—Jaundice—Irinotecan—colon cancer	0.00142	0.00704	CcSEcCtD
Triazolam—Deafness—Capecitabine—colon cancer	0.00142	0.00701	CcSEcCtD
Triazolam—Glossitis—Methotrexate—colon cancer	0.00141	0.00698	CcSEcCtD
Triazolam—Hepatic failure—Capecitabine—colon cancer	0.00141	0.00698	CcSEcCtD
Triazolam—Dysarthria—Methotrexate—colon cancer	0.00137	0.0068	CcSEcCtD
Triazolam—Stomatitis—Fluorouracil—colon cancer	0.00136	0.00674	CcSEcCtD
Triazolam—Amnesia—Capecitabine—colon cancer	0.00135	0.00668	CcSEcCtD
Triazolam—Hallucination—Vincristine—colon cancer	0.00134	0.00662	CcSEcCtD
Triazolam—Osteoarthritis—Capecitabine—colon cancer	0.00127	0.00627	CcSEcCtD
Triazolam—Visual impairment—Irinotecan—colon cancer	0.00126	0.00625	CcSEcCtD
Triazolam—Depressed level of consciousness—Methotrexate—colon cancer	0.00126	0.00621	CcSEcCtD
Triazolam—Irritability—Capecitabine—colon cancer	0.00121	0.00599	CcSEcCtD
Triazolam—Urinary retention—Capecitabine—colon cancer	0.00121	0.00596	CcSEcCtD
Triazolam—Mood swings—Capecitabine—colon cancer	0.0012	0.00594	CcSEcCtD
Triazolam—Ataxia—Capecitabine—colon cancer	0.00119	0.0059	CcSEcCtD
Triazolam—Flatulence—Irinotecan—colon cancer	0.00112	0.00556	CcSEcCtD
Triazolam—Muscular weakness—Capecitabine—colon cancer	0.00112	0.00553	CcSEcCtD
Triazolam—Muscle spasms—Irinotecan—colon cancer	0.0011	0.00543	CcSEcCtD
Triazolam—Erythema—Fluorouracil—colon cancer	0.00109	0.00541	CcSEcCtD
Triazolam—Agitation—Vincristine—colon cancer	0.00108	0.00533	CcSEcCtD
Triazolam—Sweating increased—Capecitabine—colon cancer	0.00107	0.00528	CcSEcCtD
Triazolam—Ill-defined disorder—Irinotecan—colon cancer	0.00106	0.00524	CcSEcCtD
Triazolam—Hepatic failure—Methotrexate—colon cancer	0.00105	0.0052	CcSEcCtD
Triazolam—Malaise—Irinotecan—colon cancer	0.00103	0.00509	CcSEcCtD
Triazolam—Dysuria—Capecitabine—colon cancer	0.00102	0.00507	CcSEcCtD
Triazolam—Syncope—Irinotecan—colon cancer	0.00102	0.00506	CcSEcCtD
Triazolam—Hypertension—Vincristine—colon cancer	0.00101	0.005	CcSEcCtD
Triazolam—Loss of consciousness—Irinotecan—colon cancer	0.001	0.00496	CcSEcCtD
Triazolam—Visual disturbance—Methotrexate—colon cancer	0.000996	0.00493	CcSEcCtD
Triazolam—Hypertension—Irinotecan—colon cancer	0.000985	0.00487	CcSEcCtD
Triazolam—Discomfort—Irinotecan—colon cancer	0.00096	0.00475	CcSEcCtD
Triazolam—Oedema—Vincristine—colon cancer	0.000956	0.00473	CcSEcCtD
Triazolam—Stomatitis—Capecitabine—colon cancer	0.000953	0.00471	CcSEcCtD
Triazolam—Jaundice—Capecitabine—colon cancer	0.000953	0.00471	CcSEcCtD
Triazolam—Osteoarthritis—Methotrexate—colon cancer	0.000944	0.00467	CcSEcCtD
Triazolam—Confusional state—Irinotecan—colon cancer	0.000939	0.00464	CcSEcCtD
Triazolam—Oedema—Irinotecan—colon cancer	0.000931	0.00461	CcSEcCtD
Triazolam—Chest pain—Fluorouracil—colon cancer	0.00093	0.0046	CcSEcCtD
Triazolam—Hyperhidrosis—Vincristine—colon cancer	0.000924	0.00457	CcSEcCtD
Triazolam—Discomfort—Fluorouracil—colon cancer	0.000919	0.00455	CcSEcCtD
Triazolam—Shock—Irinotecan—colon cancer	0.000916	0.00453	CcSEcCtD
Triazolam—Anorexia—Vincristine—colon cancer	0.000912	0.00451	CcSEcCtD
Triazolam—Irritability—Methotrexate—colon cancer	0.000901	0.00446	CcSEcCtD
Triazolam—Hyperhidrosis—Irinotecan—colon cancer	0.0009	0.00445	CcSEcCtD
Triazolam—Confusional state—Fluorouracil—colon cancer	0.000899	0.00445	CcSEcCtD
Triazolam—Mood swings—Methotrexate—colon cancer	0.000894	0.00442	CcSEcCtD
Triazolam—Oedema—Fluorouracil—colon cancer	0.000892	0.00441	CcSEcCtD
Triazolam—Anorexia—Irinotecan—colon cancer	0.000888	0.00439	CcSEcCtD
Triazolam—Ataxia—Methotrexate—colon cancer	0.000888	0.00439	CcSEcCtD
Triazolam—Tachycardia—Fluorouracil—colon cancer	0.000871	0.00431	CcSEcCtD
Triazolam—Insomnia—Vincristine—colon cancer	0.000865	0.00428	CcSEcCtD
Triazolam—Paraesthesia—Vincristine—colon cancer	0.000859	0.00425	CcSEcCtD
Triazolam—Anorexia—Fluorouracil—colon cancer	0.00085	0.00421	CcSEcCtD
Triazolam—Visual impairment—Capecitabine—colon cancer	0.000845	0.00418	CcSEcCtD
Triazolam—Insomnia—Irinotecan—colon cancer	0.000842	0.00417	CcSEcCtD
Triazolam—Paraesthesia—Irinotecan—colon cancer	0.000836	0.00414	CcSEcCtD
Triazolam—Decreased appetite—Vincristine—colon cancer	0.000831	0.00411	CcSEcCtD
Triazolam—Dyspnoea—Irinotecan—colon cancer	0.00083	0.00411	CcSEcCtD
Triazolam—Somnolence—Irinotecan—colon cancer	0.000828	0.0041	CcSEcCtD
Triazolam—Fatigue—Vincristine—colon cancer	0.000824	0.00408	CcSEcCtD
Triazolam—Tinnitus—Capecitabine—colon cancer	0.000818	0.00405	CcSEcCtD
Triazolam—Pain—Vincristine—colon cancer	0.000818	0.00404	CcSEcCtD
Triazolam—Constipation—Vincristine—colon cancer	0.000818	0.00404	CcSEcCtD
Triazolam—Decreased appetite—Irinotecan—colon cancer	0.00081	0.004	CcSEcCtD
Triazolam—Insomnia—Fluorouracil—colon cancer	0.000807	0.00399	CcSEcCtD
Triazolam—Fatigue—Irinotecan—colon cancer	0.000803	0.00397	CcSEcCtD
Triazolam—Paraesthesia—Fluorouracil—colon cancer	0.000801	0.00396	CcSEcCtD
Triazolam—Pain—Irinotecan—colon cancer	0.000796	0.00394	CcSEcCtD
Triazolam—Constipation—Irinotecan—colon cancer	0.000796	0.00394	CcSEcCtD
Triazolam—Dyspnoea—Fluorouracil—colon cancer	0.000795	0.00393	CcSEcCtD
Triazolam—Somnolence—Fluorouracil—colon cancer	0.000793	0.00392	CcSEcCtD
Triazolam—Gastrointestinal pain—Vincristine—colon cancer	0.000782	0.00387	CcSEcCtD
Triazolam—Decreased appetite—Fluorouracil—colon cancer	0.000775	0.00384	CcSEcCtD
Triazolam—Feeling abnormal—Irinotecan—colon cancer	0.000767	0.0038	CcSEcCtD
Triazolam—Erythema—Capecitabine—colon cancer	0.000764	0.00378	CcSEcCtD
Triazolam—Dysuria—Methotrexate—colon cancer	0.000763	0.00377	CcSEcCtD
Triazolam—Pain—Fluorouracil—colon cancer	0.000763	0.00377	CcSEcCtD
Triazolam—Gastrointestinal pain—Irinotecan—colon cancer	0.000762	0.00377	CcSEcCtD
Triazolam—Abdominal pain—Vincristine—colon cancer	0.000756	0.00374	CcSEcCtD
Triazolam—Flatulence—Capecitabine—colon cancer	0.000753	0.00372	CcSEcCtD
Triazolam—Dysgeusia—Capecitabine—colon cancer	0.000748	0.0037	CcSEcCtD
Triazolam—Abdominal pain—Irinotecan—colon cancer	0.000736	0.00364	CcSEcCtD
Triazolam—Feeling abnormal—Fluorouracil—colon cancer	0.000735	0.00364	CcSEcCtD
Triazolam—Muscle spasms—Capecitabine—colon cancer	0.000734	0.00363	CcSEcCtD
Triazolam—Drowsiness—Methotrexate—colon cancer	0.000728	0.0036	CcSEcCtD
Triazolam—Tremor—Capecitabine—colon cancer	0.000716	0.00354	CcSEcCtD
Triazolam—Stomatitis—Methotrexate—colon cancer	0.000709	0.00351	CcSEcCtD
Triazolam—Ill-defined disorder—Capecitabine—colon cancer	0.000709	0.00351	CcSEcCtD
Triazolam—Hypersensitivity—Vincristine—colon cancer	0.000705	0.00348	CcSEcCtD
Triazolam—Malaise—Capecitabine—colon cancer	0.000689	0.00341	CcSEcCtD
Triazolam—Hypersensitivity—Irinotecan—colon cancer	0.000686	0.00339	CcSEcCtD
Triazolam—Asthenia—Vincristine—colon cancer	0.000686	0.00339	CcSEcCtD
Triazolam—Syncope—Capecitabine—colon cancer	0.000685	0.00339	CcSEcCtD
Triazolam—Palpitations—Capecitabine—colon cancer	0.000675	0.00334	CcSEcCtD
Triazolam—Loss of consciousness—Capecitabine—colon cancer	0.000671	0.00332	CcSEcCtD
Triazolam—Asthenia—Irinotecan—colon cancer	0.000668	0.00331	CcSEcCtD
Triazolam—Hypertension—Capecitabine—colon cancer	0.000659	0.00326	CcSEcCtD
Triazolam—Hypersensitivity—Fluorouracil—colon cancer	0.000657	0.00325	CcSEcCtD
Triazolam—Diarrhoea—Vincristine—colon cancer	0.000654	0.00324	CcSEcCtD
Triazolam—Chest pain—Capecitabine—colon cancer	0.00065	0.00322	CcSEcCtD
Triazolam—Anxiety—Capecitabine—colon cancer	0.000648	0.00321	CcSEcCtD
Triazolam—Discomfort—Capecitabine—colon cancer	0.000642	0.00318	CcSEcCtD
Triazolam—Diarrhoea—Irinotecan—colon cancer	0.000637	0.00315	CcSEcCtD
Triazolam—Dry mouth—Capecitabine—colon cancer	0.000636	0.00315	CcSEcCtD
Triazolam—Dizziness—Vincristine—colon cancer	0.000632	0.00313	CcSEcCtD
Triazolam—Pruritus—Fluorouracil—colon cancer	0.000631	0.00312	CcSEcCtD
Triazolam—Visual impairment—Methotrexate—colon cancer	0.000629	0.00311	CcSEcCtD
Triazolam—Confusional state—Capecitabine—colon cancer	0.000628	0.00311	CcSEcCtD
Triazolam—Oedema—Capecitabine—colon cancer	0.000623	0.00308	CcSEcCtD
Triazolam—Dizziness—Irinotecan—colon cancer	0.000616	0.00305	CcSEcCtD
Triazolam—Shock—Capecitabine—colon cancer	0.000613	0.00303	CcSEcCtD
Triazolam—Diarrhoea—Fluorouracil—colon cancer	0.00061	0.00302	CcSEcCtD
Triazolam—Tinnitus—Methotrexate—colon cancer	0.000609	0.00301	CcSEcCtD
Triazolam—Tachycardia—Capecitabine—colon cancer	0.000608	0.00301	CcSEcCtD
Triazolam—Vomiting—Vincristine—colon cancer	0.000608	0.00301	CcSEcCtD
Triazolam—Hyperhidrosis—Capecitabine—colon cancer	0.000603	0.00298	CcSEcCtD
Triazolam—Dermatitis—Vincristine—colon cancer	0.000602	0.00298	CcSEcCtD
Triazolam—Headache—Vincristine—colon cancer	0.000599	0.00296	CcSEcCtD
Triazolam—Anorexia—Capecitabine—colon cancer	0.000594	0.00294	CcSEcCtD
Triazolam—Vomiting—Irinotecan—colon cancer	0.000592	0.00293	CcSEcCtD
Triazolam—Dizziness—Fluorouracil—colon cancer	0.00059	0.00292	CcSEcCtD
Triazolam—Dermatitis—Irinotecan—colon cancer	0.000587	0.0029	CcSEcCtD
Triazolam—Headache—Irinotecan—colon cancer	0.000583	0.00289	CcSEcCtD
Triazolam—Erythema—Methotrexate—colon cancer	0.000569	0.00281	CcSEcCtD
Triazolam—Nausea—Vincristine—colon cancer	0.000568	0.00281	CcSEcCtD
Triazolam—Vomiting—Fluorouracil—colon cancer	0.000567	0.00281	CcSEcCtD
Triazolam—Insomnia—Capecitabine—colon cancer	0.000564	0.00279	CcSEcCtD
Triazolam—Dermatitis—Fluorouracil—colon cancer	0.000562	0.00278	CcSEcCtD
Triazolam—Paraesthesia—Capecitabine—colon cancer	0.00056	0.00277	CcSEcCtD
Triazolam—Headache—Fluorouracil—colon cancer	0.000559	0.00276	CcSEcCtD
Triazolam—Dysgeusia—Methotrexate—colon cancer	0.000557	0.00275	CcSEcCtD
Triazolam—Dyspnoea—Capecitabine—colon cancer	0.000556	0.00275	CcSEcCtD
Triazolam—Nausea—Irinotecan—colon cancer	0.000553	0.00274	CcSEcCtD
Triazolam—Decreased appetite—Capecitabine—colon cancer	0.000542	0.00268	CcSEcCtD
Triazolam—Fatigue—Capecitabine—colon cancer	0.000537	0.00266	CcSEcCtD
Triazolam—Pain—Capecitabine—colon cancer	0.000533	0.00264	CcSEcCtD
Triazolam—Constipation—Capecitabine—colon cancer	0.000533	0.00264	CcSEcCtD
Triazolam—Nausea—Fluorouracil—colon cancer	0.00053	0.00262	CcSEcCtD
Triazolam—Ill-defined disorder—Methotrexate—colon cancer	0.000528	0.00261	CcSEcCtD
Triazolam—Feeling abnormal—Capecitabine—colon cancer	0.000514	0.00254	CcSEcCtD
Triazolam—Malaise—Methotrexate—colon cancer	0.000513	0.00254	CcSEcCtD
Triazolam—Gastrointestinal pain—Capecitabine—colon cancer	0.00051	0.00252	CcSEcCtD
Triazolam—Abdominal pain—Capecitabine—colon cancer	0.000493	0.00244	CcSEcCtD
Triazolam—Chest pain—Methotrexate—colon cancer	0.000484	0.00239	CcSEcCtD
Triazolam—Discomfort—Methotrexate—colon cancer	0.000478	0.00237	CcSEcCtD
Triazolam—Confusional state—Methotrexate—colon cancer	0.000468	0.00231	CcSEcCtD
Triazolam—Hypersensitivity—Capecitabine—colon cancer	0.000459	0.00227	CcSEcCtD
Triazolam—Hyperhidrosis—Methotrexate—colon cancer	0.000449	0.00222	CcSEcCtD
Triazolam—Asthenia—Capecitabine—colon cancer	0.000447	0.00221	CcSEcCtD
Triazolam—Anorexia—Methotrexate—colon cancer	0.000442	0.00219	CcSEcCtD
Triazolam—Pruritus—Capecitabine—colon cancer	0.000441	0.00218	CcSEcCtD
Triazolam—Diarrhoea—Capecitabine—colon cancer	0.000426	0.00211	CcSEcCtD
Triazolam—Insomnia—Methotrexate—colon cancer	0.00042	0.00208	CcSEcCtD
Triazolam—Paraesthesia—Methotrexate—colon cancer	0.000417	0.00206	CcSEcCtD
Triazolam—Dyspnoea—Methotrexate—colon cancer	0.000414	0.00205	CcSEcCtD
Triazolam—Somnolence—Methotrexate—colon cancer	0.000412	0.00204	CcSEcCtD
Triazolam—Dizziness—Capecitabine—colon cancer	0.000412	0.00204	CcSEcCtD
Triazolam—Decreased appetite—Methotrexate—colon cancer	0.000403	0.002	CcSEcCtD
Triazolam—Fatigue—Methotrexate—colon cancer	0.0004	0.00198	CcSEcCtD
Triazolam—Pain—Methotrexate—colon cancer	0.000397	0.00196	CcSEcCtD
Triazolam—Vomiting—Capecitabine—colon cancer	0.000396	0.00196	CcSEcCtD
Triazolam—Dermatitis—Capecitabine—colon cancer	0.000393	0.00194	CcSEcCtD
Triazolam—Headache—Capecitabine—colon cancer	0.00039	0.00193	CcSEcCtD
Triazolam—Feeling abnormal—Methotrexate—colon cancer	0.000382	0.00189	CcSEcCtD
Triazolam—Gastrointestinal pain—Methotrexate—colon cancer	0.000379	0.00188	CcSEcCtD
Triazolam—Nausea—Capecitabine—colon cancer	0.00037	0.00183	CcSEcCtD
Triazolam—Abdominal pain—Methotrexate—colon cancer	0.000367	0.00181	CcSEcCtD
Triazolam—Hypersensitivity—Methotrexate—colon cancer	0.000342	0.00169	CcSEcCtD
Triazolam—Asthenia—Methotrexate—colon cancer	0.000333	0.00165	CcSEcCtD
Triazolam—Pruritus—Methotrexate—colon cancer	0.000328	0.00162	CcSEcCtD
Triazolam—Diarrhoea—Methotrexate—colon cancer	0.000317	0.00157	CcSEcCtD
Triazolam—Dizziness—Methotrexate—colon cancer	0.000307	0.00152	CcSEcCtD
Triazolam—Vomiting—Methotrexate—colon cancer	0.000295	0.00146	CcSEcCtD
Triazolam—Dermatitis—Methotrexate—colon cancer	0.000292	0.00145	CcSEcCtD
Triazolam—Headache—Methotrexate—colon cancer	0.000291	0.00144	CcSEcCtD
Triazolam—Nausea—Methotrexate—colon cancer	0.000276	0.00136	CcSEcCtD
